p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

  • Bioorg Med Chem Lett. 2001 Jan 8;11(1):9-12. doi: 10.1016/s0960-894x(00)00574-6.
A M Redman  1 ,  J S Johnson ,  R Dally ,  S Swartz ,  H Wild ,  H Paulsen ,  Y Caringal ,  D Gunn ,  J Renick ,  M Osterhout ,  J Kingery-Wood ,  R A Smith ,  W Lee ,  J Dumas ,  S M Wilhelm ,  T J Housley ,  A Bhargava ,  G E Ranges ,  A Shrikhande ,  D Young ,  M Bombara ,  W J Scott
Affiliations
  • 1. Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA. [email protected]
PMID: 11140741 DOI: 10.1016/s0960-894x(00)00574-6
Abstract

Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and Other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.